Cardiology

Evolocumab: Is LDL-C reduction finally translating to lives saved?

Evolocumab, a PCSK9 inhibitor, has demonstrated a potential to reduce the risk of death in patients at high cardiovascular risk, offering a critical addition to lipid-lowering strategies.

Tactical athletes need more than a sports physical

New recommendations address cardiovascular screening and management for tactical athletes, focusing on unique physiological demands and risk factors in this population.

GLP-1s: Is eligibility missing half your high-risk patients?

A 313,000-person Danish and UK analysis finds people with a BMI of 25-26.9, currently ineligible for GLP-1 receptor agonists, have coronary heart disease risk matching those who do qualify, if they also carry elevated remnant cholesterol or inflammation.

Rethinking xylitol: Is this 'healthy' sugar substitute a cardiac threat?

Xylitol, a common sugar alcohol, has been linked to an elevated risk for major adverse cardiovascular events, raising concerns about its widespread use.

Hypertension: Do shorter wall squats work as well for older women?

Isometric wall squats reduced blood pressure in older women with hypertension, but a higher dose did not offer superior postexercise hypotension.

Beyond diagnosis: ECG waveforms predict MI-E treatment response

Electrocardiogram waveforms offer insights into myocardial infarction with epicardial coronary artery disease (MI-E) efficacy, providing a non-invasive window into myocardial health.

Endocarditis: Why fixed-dose ampicillin often misses the mark

A personalized antibiotic strategy, guided by therapeutic drug monitoring, optimizes ampicillin regimens in enterococcal bloodstream infections and endocarditis.

LAA occlusion: Less bleeding, but is stroke risk truly equal?

Left atrial appendage occlusion (LAAO) reduces nonprocedural bleeding in AF patients but shows no difference in stroke or mortality compared to medical therapy.

Eplontersen for ATTR-CM: Why a promising therapy fell short

Eplontersen, when added to standard care, did not demonstrate additional cardiovascular benefit for patients with ATTR-CM. The therapy's impact on cardiac outcomes remains unconfirmed.